TRAIL is a well-documented anti-cancer agent and is often efficacious in drug combination in vitro, although it has been less promising in clinical trials [15] due to a short half-life, ineffective dosing at the tumor site, and TRAIL resistance. This evidence concerns the gene TNFSF10 and cancer.